For primary hyperlipidemia due to heterologous familial hypercholesterolemia (HeFH) and HoFH, statins and PCSK9 inhibitors (that function by increasing the number of LDL receptors) are less effective in treatment due to the absence of LDL receptor expression. This evidence concerns the gene LDLR and familial hypercholesterolemia.